Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study is looking for adults with a specific type of cancer called gastroenteropancreatic neuroendocrine tumours (GEP-NETs). This is for people whose cancer has spread and can't be removed by surgery, and where their previous treatment with Lutetium-177 has stopped working. The study is comparing a new medication called RYZ101 with existing standard treatments like Everolimus, Sunitinib, Octreotide, or Lanreotide. We want to find out if RYZ101 is safe, how it works in the body, and how effective it is at controlling the cancer compared to the standard options. The study aims to improve treatments for this type of cancer.
Auf einen Blick
Worum geht es in dieser Studie?
This research study is about a type of cancer called gastroenteropancreatic neuroendocrine tumours, often shortened to GEP-NETs. These cancers start in special cells found in your gut or pancreas. For some people, these cancers can grow or spread and can't be removed by surgery. When this happens, doctors use treatments that help control the cancer, but these treatments don't always stop the cancer from growing for good.
This study is looking for people whose GEP-NETs have continued to grow even after they've had a specific type of treatment called Lutetium-177. We are testing a new medicine called RYZ101. The main goal is to see if RYZ101 can be a safe and effective new option for these patients. We will compare it to common treatments that doctors already use, such as Everolimus, Sunitinib, Octreotide, or Lanreotide, to see if RYZ101 works better at controlling the cancer's growth and spread.
The study has two parts. The first part helps us understand the best dose of RYZ101 and how it moves through the body. The second and main part of the study will seriously compare this new medicine with standard treatments to understand its safety and how well it works. This research is important because it could lead to new and better ways to treat GEP-NETs for people who have limited options.
Wichtige Erkenntnisse
- This study is for adults with a specific type of GEP-NET cancer.
- Your cancer must have progressed after previous Lutetium-177 treatment.
- The study compares a new medicine (RYZ101) with standard treatments.
- It aims to find out if RYZ101 is safe and more effective.
- Participation involves regular hospital visits, tests, and medical monitoring.
Wer könnte berechtigt sein?
To be considered for this study, you would need to have specific type of GEP-NET cancer that has been confirmed by a doctor. Your cancer must be well-differentiated (meaning the cells still look a bit like normal cells) and growing, and can't be removed by surgery. Importantly, your cancer must have grown even after you've already had Lutetium-177 treatment, and it should show up on a special type of scan called an SSTR-PET scan.
You also need to be generally well enough to take part, meaning you can mostly look after yourself. Your kidneys, blood, and liver need to be working properly, which will be checked with blood tests. There are some conditions that would mean you couldn't join. For example, if you've already had certain types of radiation treatment called radioembolisation or if you have serious heart problems like severe heart failure or very high blood pressure that can't be controlled with medicines. Also, if your diabetes is not well managed, you might not be able to participate.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Have you been diagnosed with an inoperable GEP-NET cancer?
- Has your GEP-NET cancer grown after Lutetium-177 (Lu-177) treatment?
- Do you feel generally well enough for a study, with good organ function?
- Do you have any serious heart conditions or very high blood pressure?
- Is your diabetes well controlled (if you have diabetes)?
Was beinhaltet die Teilnahme?
If you join this study, it will involve regular hospital visits, where you'll have check-ups, blood tests, and scans (like SSTR-PET scans) to monitor your health and how your cancer is responding. Some visits might be more frequent at the beginning. You will receive either the new medicine RYZ101 or one of the standard treatments (Everolimus, Sunitinib, Octreotide, or Lanreotide). You won't get to choose which treatment you receive; this is decided randomly, like flipping a coin. You will continue treatment for as long as it is benefiting you and you are tolerating it well. After your treatment ends, there will be follow-up calls or visits to see how you are doing. The total time you're involved in the study can vary, depending on how you respond to the treatment, but it will involve ongoing monitoring.
Potenzielle Risiken und Vorteile
Locations (54)
- Research FacilityVerifizierte PostleitzahlPhoenix, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlDuarte, Vereinigte Staaten· Abgeschlossen
- Research FacilityVerifizierte PostleitzahlIrvine, Vereinigte Staaten· Rekrutierung
- Research FacilityVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlPalo Alto, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlSan Francisco, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlNew Haven, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlWashington D.C., Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlJacksonville, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Research FacilityVerifizierte PostleitzahlMiami, Vereinigte Staaten· Rekrutierung
- Research FacilityVerifizierte PostleitzahlTampa, Vereinigte Staaten· Rekrutierung
- Research FacilityVerifizierte PostleitzahlAtlanta, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
Häufige Fragen
What are GEP-NETs?
GEP-NETs are a type of cancer that starts in certain hormone-producing cells found in your gut (gastrointestinal tract) or pancreas.
What does 'inoperable' mean?
It means the cancer cannot be completely removed by surgery, often because it has spread or is in a difficult location.
What is Lutetium-177 treatment?
This is a type of radiation treatment where a radioactive substance is targeted directly to your cancer cells to help stop their growth.
Will I definitely get the new drug RYZ101?
No, you will be randomly assigned to receive either RYZ101 or one of the standard treatments that are already used for this type of cancer.
What is the aim of this study?
The study aims to see if the new medicine RYZ101 is safe and works better than current treatments for people with GEP-NETs whose cancer has progressed after Lutetium-177 treatment.
Wie Sie mehr erfahren können
RayzeBio Clinical Trials
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.